Barclays
SPRB

Barclays’s Spruce Biosciences SPRB Stock Holding History

Barclays’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4K Buy
+674
New +$37.7K ﹤0.01% 4426
2023
Q2 		– Sell
-100
Closed -$16.5K – 5171
2023
Q1 		$16.5K Sell
100
-2
-2% -$371 ﹤0.01% 4686
2022
Q4 		$8.38K Sell
102
-51
-33% -$4.27K ﹤0.01% 4944
2022
Q3 		$15K Hold
153
– – ﹤0.01% 4171
2022
Q2 		$20K Sell
153
-16
-9% -$2.05K ﹤0.01% 4415
2022
Q1 		$25K Buy
+169
New +$31.4K ﹤0.01% 4381

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Barclays's SPRB Position: Q2 2026 in Review

Barclays opened a new position in Spruce Biosciences (SPRB) in Q2 2026: 674 shares worth $36.4K. The stake represents ﹤0.01% of the portfolio and ranks #4426 among its holdings. This is a return to the name: Barclays previously reported a position in SPRB as recently as Q1 2023.

Barclays first reported a position in SPRB in Q1 2022 and has held it in 6 quarters since. 63 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Barclays held 674 shares of Spruce Biosciences worth $36.4K as of Q2 2026.
  • Spruce Biosciences was a new Barclays position in Q2 2026.
  • Spruce Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4426 holding.
  • Barclays first reported a position in Spruce Biosciences in Q1 2022 and has held it in 6 quarters since.
  • 63 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.